부산대학교 도서관

Objectives: To evaluate the ability of magnetic resonance imaging (MRI)‐targeted biopsy combined with systematic biopsy (MRI‐biopsy) to reduce negative biopsies and detect clinically significant prostate cancer compared to systematic biopsy (SB) alone in the confirmatory biopsy setting using matched cohorts. Patients and Methods: Patients were identified from an active surveillance database who had a previously positive transrectal ultrasonography‐guided SB followed by a confirmatory biopsy at a single institution between 2006 and 2019. Patients were divided into two cohorts based on confirmatory biopsy technique: SB alone or MRI‐biopsy (which included MRI‐targeted and systematic biopsies). Cohorts were then matched on age, prostate‐specific antigen (PSA) level, number of positive cores on initial biopsy and initial biopsy Gleason grade group (GG). Logistic regression was performed to identify associations with confirmatory biopsy upgrading. Results: After matching, 514 patients were identified (257 per cohort). PSA, prostate volume and PSA density prior to initial biopsy, in addition to total number of initial biopsy positive cores and GG, were similar between the matched cohorts. After confirmatory biopsy, 118/257 patients (45.9%) in the MRI‐biopsy cohort were upgraded compared to 46/257 patients (17.9%) in the SB cohort (P < 0.001). The rate of negative confirmatory biopsy was 32/257 (12.5%) compared to 97/257 (37.7%) in the MRI‐biopsy and SB cohorts, respectively (P < 0.001). Confirmatory MRI‐biopsy was associated with greater odds of confirmatory biopsy upgrade from GG 1 to ≥GG 2 compared to SB alone (odds ratio 3.62, 95% confidence interval 1.97–6.63; P < 0.001). Conclusion: The addition of MRI‐targeted biopsies to SB in the confirmatory biopsy setting among men with previously detected prostate cancer resulted in fewer negative confirmatory biopsies and detection of more clinically significant prostate cancer compared to SB alone. [ABSTRACT FROM AUTHOR]